# A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

> **NCT03172494** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 720 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin degludec/liraglutide
- **DRUG:** Insulin degludec
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT03172494
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-26
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-07-13
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172494, "A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03172494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*